.jetcityimage/iStock Editorial via Getty Images Morgan Stanley has chosen Eli Lilly (NYSE: LLY) as its own leading biopharma choice for 2025 and also measured yet another 9 labels in the room as obese. The assets bank pointed out in a note that it continues to strongly believe “diabesity is set to come to be.